Treatment of Pulmonary Anthrax in Neonates 32–44 Weeks Postmenstrual Age
This protocol addresses systemic anthrax (inhalation/pulmonary) — with or without meningitis — in preterm and full-term newborns whose postmenstrual age (gestational age plus chronologic age) falls between 32 and 44 weeks.
Clinical scenario
Patients in this population are neonates in the postmenstrual age range of 32 to 44 weeks. This includes preterm infants at various gestational ages as well as full-term newborns within the first weeks of life. The infection involves systemic anthrax via the pulmonary (inhalation) route, and meningeal involvement may or may not be present.
Because neonates are immune-compromised hosts, empiric treatment must be adapted to gestational and chronologic age, and a longer duration of therapy may be required to achieve cure.
Approach to treatment
Preferred management involves combination antimicrobial therapy — drawing from multiple bactericidal drug classes together with a protein synthesis inhibitor — alongside a single antitoxin agent as adjunctive therapy.
Full drug selection, dosing by gestational and chronologic age, and transition criteria are detailed in the complete protocol →
References
- For preterm and full-term newborns 32–44 weeks' postmenstrual age (i.e., gestational age plus chronologic age), empiric treatment regimens for those with systemic anthrax with or without meningitis (Table 17) are summarized as follows:
- Antimicrobial drugs: Choose two bactericidal drugs from different antimicrobial drug classes plus a PSI or an RNAI.
- Antitoxin: Choose a single antitoxin as adjunctive therapy.
- Duration of antimicrobial drug treatment should be for 2 weeks or longer, although as immune-compromised hosts, neonates might require a longer duration of therapy to achieve cure.
- Transition from IV administration to oral medication for neonates tolerating regular feeding should be based on patient improvement and clinical judgment.
View source ↗